Symbols / ANNX Stock $5.84 +6.09% Annexon, Inc.

Healthcare • Biotechnology • United States • NMS
ANNX (Stock) Chart
About

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 936.37M
Enterprise Value 670.46M Income -208.55M Sales —
Book/sh 1.42 Cash/sh 1.49 Dividend Yield —
Payout 0.00% Employees 96 IPO —
P/E — Forward P/E -5.92 PEG —
P/S — P/B 4.12 P/C —
EV/EBITDA -3.13 EV/Sales — Quick Ratio 5.59
Current Ratio 5.68 Debt/Eq 12.38 LT Debt/Eq —
EPS (ttm) -1.34 EPS next Y -0.99 EPS Growth —
Revenue Growth — Earnings 2026-05-11 ROA -43.10%
ROE -81.90% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 160.47M
Shs Float 130.72M Short Float 12.87% Short Ratio 6.31
Short Interest — 52W High 7.18 52W Low 1.28
Beta 1.15 Avg Volume 2.65M Volume 1.88M
Target Price $13.71 Recom Strong_buy Prev Close $5.50
Price $5.83 Change 6.09%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$13.71
Mean price target
2. Current target
$5.84
Latest analyst target
3. DCF / Fair value
$-11.72
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.84
Low
$8.00
High
$27.00
Mean
$13.71

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-20 main Chardan Capital Buy → Buy $16
2025-12-23 init Chardan Capital — → Buy $16
2025-12-02 init Clear Street — → Buy $17
2025-11-19 main Wells Fargo Overweight → Overweight $27
2025-08-15 reit HC Wainwright & Co. Buy → Buy $14
2025-05-14 main HC Wainwright & Co. Buy → Buy $14
2025-05-13 main Needham Buy → Buy $11
2025-03-04 reit Needham Buy → Buy $16
2024-12-17 reit HC Wainwright & Co. Buy → Buy $30
2024-11-15 reit Cantor Fitzgerald — → Overweight —
2024-11-15 reit HC Wainwright & Co. Buy → Buy $30
2024-11-15 reit Needham Buy → Buy $16
2024-09-09 reit Cantor Fitzgerald — → Overweight —
2024-08-13 reit HC Wainwright & Co. Buy → Buy $30
2024-08-13 reit Needham Buy → Buy $16
2024-06-05 reit Cantor Fitzgerald — → Overweight —
2024-06-04 reit Needham Buy → Buy $16
2024-06-04 reit HC Wainwright & Co. Buy → Buy $30
2024-05-15 main Wells Fargo Overweight → Overweight $10
2024-05-14 reit HC Wainwright & Co. Buy → Buy $30
News
RSS: Latest ANNX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-10 CARSON WILLIAM H. Director — 8,000 $5.67 $45,360
2026-03-02 LEW JENNIFER Chief Financial Officer — 5,565 $5.42 $30,162
2026-03-02 DANANBERG JAMIE Officer — 5,820 $5.43 $31,603
2026-03-02 OVERDORF MICHAEL Officer — 4,339 $5.42 $23,517
2026-03-02 YEDNOCK TED Officer — 5,566 $5.42 $30,168
2026-03-02 ARTIS DEAN RICHARD PH.D. Officer — 5,894 $5.43 $32,004
2026-02-19 LEW JENNIFER Chief Financial Officer — 62,500 $0.00 $0
2026-02-19 DANANBERG JAMIE Officer — 56,250 $0.00 $0
2026-02-19 OVERDORF MICHAEL Officer — 62,500 $0.00 $0
2026-02-19 YEDNOCK TED Officer — 62,500 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
216.41
+40.46%
154.07
+7.20%
143.72
-1.29%
145.60
Research And Development
184.70
+54.63%
119.45
+5.00%
113.76
+1.12%
112.50
Selling General And Administration
29.06
-9.27%
32.03
+14.30%
28.02
-9.45%
30.95
General And Administrative Expense
29.06
-9.27%
32.03
+14.30%
28.02
-9.45%
30.95
Salaries And Wages
15.61
-7.39%
16.86
+2.77%
16.40
-4.57%
17.19
Other Gand A
13.45
-11.36%
15.17
+30.58%
11.62
-15.56%
13.76
Total Expenses
216.41
+40.46%
154.07
+7.20%
143.72
-1.29%
145.60
Operating Income
-216.41
-40.46%
-154.07
-7.20%
-143.72
+1.29%
-145.60
Total Operating Income As Reported
-216.41
-40.46%
-154.07
-7.20%
-143.72
+1.29%
-145.60
EBITDA
-213.76
-41.12%
-151.47
-6.99%
-141.57
+1.31%
-143.45
Normalized EBITDA
-213.76
-41.12%
-151.47
-6.99%
-141.57
+1.31%
-143.45
Reconciled Depreciation
2.17
+0.74%
2.15
+0.09%
2.15
+1.99%
2.11
EBIT
-216.41
-40.46%
-154.07
-7.20%
-143.72
+1.29%
-145.60
Net Income
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Pretax Income
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Net Non Operating Interest Income Expense
9.72
-38.78%
15.87
+67.33%
9.49
+159.75%
3.65
Net Interest Income
9.72
-38.78%
15.87
+67.33%
9.49
+159.75%
3.65
Interest Income Non Operating
9.72
-38.78%
15.87
+67.33%
9.49
+159.75%
3.65
Interest Income
9.72
-38.78%
15.87
+67.33%
9.49
+159.75%
3.65
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Net Income From Continuing Operation Net Minority Interest
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Net Income From Continuing And Discontinued Operation
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Net Income Continuous Operations
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Normalized Income
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Net Income Common Stockholders
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-1.01
+42.94%
-1.77
+31.92%
-2.60
Basic EPS
—
-1.01
+42.94%
-1.77
+31.92%
-2.60
Basic Average Shares
—
137.40
+81.58%
75.67
+38.41%
54.67
Diluted Average Shares
—
137.40
+81.58%
75.67
+38.41%
54.67
Diluted NI Availto Com Stockholders
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Depreciation Amortization Depletion Income Statement
2.65
+2.00%
2.60
+33.50%
1.95
-9.57%
2.15
Depreciation And Amortization In Income Statement
2.65
+2.00%
2.60
+33.50%
1.95
-9.57%
2.15
Depreciation Income Statement
2.65
+2.00%
2.60
+33.50%
1.95
-9.57%
2.15
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
277.57
-20.71%
350.07
+17.60%
297.67
+4.41%
285.10
Current Assets
242.19
-23.47%
316.46
+19.94%
263.86
+6.35%
248.10
Cash Cash Equivalents And Short Term Investments
238.34
-23.61%
312.02
+20.14%
259.72
+7.03%
242.66
Cash And Cash Equivalents
162.05
+227.39%
49.50
-78.01%
225.11
+60.77%
140.02
Cash Equivalents
160.04
+241.62%
46.85
-78.37%
216.62
+55.34%
139.45
Cash Financial
2.01
-24.07%
2.65
-68.77%
8.49
+1389.12%
0.57
Other Short Term Investments
76.29
-70.94%
262.52
+658.59%
34.61
-66.28%
102.64
Receivables
—
—
—
—
Prepaid Assets
2.60
-22.04%
3.34
+0.57%
3.32
-36.60%
5.24
Other Current Assets
1.24
+12.50%
1.10
+34.14%
0.82
+305.42%
0.20
Total Non Current Assets
35.38
+5.27%
33.61
-0.60%
33.81
-8.61%
37.00
Net PPE
25.80
-12.07%
29.34
-10.49%
32.78
-8.85%
35.97
Gross PPE
35.15
-3.76%
36.52
-3.41%
37.81
-2.67%
38.85
Accumulated Depreciation
-9.35
-30.17%
-7.18
-42.75%
-5.03
-74.44%
-2.88
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.82
+13.38%
0.72
+0.00%
0.72
-0.14%
0.73
Other Properties
17.06
-7.98%
18.54
-6.54%
19.84
-5.03%
20.89
Leases
17.26
+0.05%
17.25
+0.05%
17.25
+0.08%
17.23
Other Non Current Assets
9.58
+124.47%
4.27
+313.47%
1.03
+0.00%
1.03
Total Liabilities Net Minority Interest
65.92
+15.72%
56.97
+20.90%
47.12
-12.59%
53.90
Current Liabilities
42.63
+39.72%
30.51
+70.19%
17.93
-19.82%
22.36
Payables And Accrued Expenses
31.70
+43.94%
22.02
+119.87%
10.02
-35.66%
15.56
Payables
14.93
+43.21%
10.43
+90.01%
5.49
-26.01%
7.42
Accounts Payable
14.93
+43.21%
10.43
+90.01%
5.49
-26.01%
7.42
Current Accrued Expenses
16.77
+44.60%
11.59
+156.05%
4.53
-44.43%
8.15
Pensionand Other Post Retirement Benefit Plans Current
7.52
+28.87%
5.83
+4.03%
5.61
+5.81%
5.30
Current Debt And Capital Lease Obligation
2.91
+15.49%
2.52
+16.30%
2.17
+64.51%
1.32
Current Capital Lease Obligation
2.91
+15.49%
2.52
+16.30%
2.17
+64.51%
1.32
Current Deferred Liabilities
—
—
—
—
Other Current Liabilities
0.51
+260.99%
0.14
+0.00%
0.14
-21.67%
0.18
Total Non Current Liabilities Net Minority Interest
23.29
-11.95%
26.45
-9.37%
29.19
-7.46%
31.54
Long Term Debt And Capital Lease Obligation
23.29
-11.95%
26.45
-9.37%
29.19
-7.46%
31.54
Long Term Capital Lease Obligation
23.29
-11.95%
26.45
-9.37%
29.19
-7.46%
31.54
Non Current Deferred Liabilities
—
—
—
—
Stockholders Equity
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Common Stock Equity
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Capital Stock
0.15
+36.70%
0.11
+39.74%
0.08
+62.50%
0.05
Common Stock
0.15
+36.70%
0.11
+39.74%
0.08
+62.50%
0.05
Preferred Stock
—
—
—
—
Share Issued
149.36
+36.55%
109.38
+39.57%
78.37
+64.22%
47.72
Ordinary Shares Number
149.36
+36.55%
109.38
+39.57%
78.37
+64.22%
47.72
Additional Paid In Capital
1,128.92
+12.48%
1,003.68
+21.95%
823.03
+22.88%
669.78
Retained Earnings
-917.39
-29.08%
-710.70
-24.14%
-572.50
-30.63%
-438.26
Gains Losses Not Affecting Retained Earnings
-0.03
-390.00%
0.01
+119.23%
-0.05
+86.02%
-0.37
Other Equity Adjustments
-0.03
-390.00%
0.01
+119.23%
-0.05
+86.02%
-0.37
Total Equity Gross Minority Interest
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Total Capitalization
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Working Capital
199.56
-30.21%
285.95
+16.27%
245.93
+8.95%
225.74
Invested Capital
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Total Debt
26.20
-9.56%
28.97
-7.60%
31.36
-4.57%
32.86
Capital Lease Obligations
26.20
-9.56%
28.97
-7.60%
31.36
-4.57%
32.86
Net Tangible Assets
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Tangible Book Value
211.65
-27.79%
293.11
+16.98%
250.56
+8.37%
231.19
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-186.36
-57.92%
-118.01
+2.59%
-121.14
-4.16%
-116.31
Cash Flow From Continuing Operating Activities
-186.36
-57.92%
-118.01
+2.59%
-121.14
-4.16%
-116.31
Net Income From Continuing Operations
-206.69
-49.56%
-138.20
-2.95%
-134.24
+5.43%
-141.95
Depreciation Amortization Depletion
2.17
+0.74%
2.15
+0.09%
2.15
+1.99%
2.11
Depreciation And Amortization
2.17
+0.74%
2.15
+0.09%
2.15
+1.99%
2.11
Other Non Cash Items
1.52
+16.56%
1.30
+16.53%
1.12
-7.14%
1.21
Stock Based Compensation
16.42
-15.49%
19.43
+6.87%
18.18
-1.80%
18.52
Change In Working Capital
4.23
-33.50%
6.36
+209.58%
-5.80
-255.30%
3.74
Change In Prepaid Assets
0.60
+299.33%
-0.30
-122.19%
1.35
+392.01%
-0.46
Change In Payables And Accrued Expense
11.71
-4.20%
12.23
+316.27%
-5.65
-195.98%
5.89
Change In Accrued Expense
7.22
-0.95%
7.29
+303.86%
-3.58
-157.90%
6.18
Change In Payable
4.49
-9.02%
4.94
+337.65%
-2.08
-623.69%
-0.29
Change In Account Payable
4.49
-9.02%
4.94
+337.65%
-2.08
-623.69%
-0.29
Change In Other Current Assets
-5.31
-66.80%
-3.18
0.00
—
Change In Other Current Liabilities
-2.77
-16.28%
-2.38
-58.55%
-1.50
+11.07%
-1.69
Investing Cash Flow
190.05
+186.86%
-218.80
-409.46%
70.70
+20.98%
58.44
Cash Flow From Continuing Investing Activities
190.05
+186.86%
-218.80
-409.46%
70.70
+20.98%
58.44
Net PPE Purchase And Sale
-0.14
-813.33%
-0.01
+92.23%
-0.19
+97.04%
-6.53
Purchase Of PPE
-0.14
-813.33%
-0.01
+92.23%
-0.19
+97.04%
-6.53
Capital Expenditure
-0.14
-813.33%
-0.01
+92.23%
-0.19
+97.04%
-6.53
Net Investment Purchase And Sale
190.19
+186.93%
-218.78
-408.60%
70.90
+9.12%
64.97
Purchase Of Investment
-212.21
+63.66%
-583.93
-440.24%
-108.09
+4.51%
-113.20
Sale Of Investment
402.40
+10.20%
365.15
+104.01%
178.98
+0.46%
178.17
Financing Cash Flow
108.86
-32.47%
161.21
+18.95%
135.52
+10.26%
122.91
Cash Flow From Continuing Financing Activities
108.86
-32.47%
161.21
+18.95%
135.52
+10.26%
122.91
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
109.56
-32.32%
161.87
+19.45%
135.51
+3.86%
130.48
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
0.92
-42.60%
1.59
+180.14%
0.57
+35.48%
0.42
Net Other Financing Charges
-1.62
+28.33%
-2.26
-307.03%
-0.56
+93.05%
-7.99
Changes In Cash
112.55
+164.10%
-175.60
-306.38%
85.08
+30.82%
65.04
Effect Of Exchange Rate Changes
0.00
+113.33%
-0.01
-400.00%
0.01
+400.00%
0.00
Beginning Cash Position
50.53
-77.66%
226.14
+60.33%
141.05
+85.57%
76.01
End Cash Position
163.08
+222.74%
50.53
-77.66%
226.14
+60.33%
141.05
Free Cash Flow
-186.49
-58.02%
-118.02
+2.73%
-121.33
+1.22%
-122.83
Income Tax Paid Supplemental Data
5.07
+3.52%
4.89
+3.49%
4.73
—
Amortization Of Securities
-4.00
+55.77%
-9.05
-255.06%
-2.55
-3593.15%
0.07
Common Stock Issuance
109.56
-32.32%
161.87
+19.45%
135.51
+3.86%
130.48
Issuance Of Capital Stock
109.56
-32.32%
161.87
+19.45%
135.51
+3.86%
130.48
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
Preferred Stock Payments
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category